CVRx (CVRX) Preferred Stock Liabilities (2020 - 2021)
CVRx's quarterly Preferred Stock Liabilities came in at $330.0 million in Q2 2021, up 17.86% year-on-year from $280.0 million in Q2 2020, and little changed quarter-over-quarter from $330.0 million in Q1 2021.
CVRx has reported Preferred Stock Liabilities for 2 years, with the latest figure at $330.0 million in Q2 2021.
- For the quarter ending Q2 2021, Preferred Stock Liabilities rose 17.86% year-over-year to $330.0 million; the trailing twelve-month figure through Jun 2021 stood at $330.0 million (up 17.86% YoY), and the FY2020 full-year result was $330.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2021 stood at $330.0 million, roughly flat from $330.0 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $330.0 million in Q3 2020, with the low at $280.0 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | CVRx | 144.43 Mn | 72.13 Mn | 12.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 329.98 Mn |
| Mar 31, 2021 | 329.98 Mn |
| Dec 31, 2020 | 329.98 Mn |
| Sep 30, 2020 | 329.98 Mn |
| Jun 30, 2020 | 279.98 Mn |